Henry Schein Raises 2026 Guidance After Strong Q2 Revenue
Henry Schein lifts full-year guidance on $3.46B Q2 revenue, with EPS target now $5.29–$5.39 and sales growth up to 5.5%.
Henry Schein just gave traders a reason to pay attention. The dental and medical supply giant posted second-quarter revenue of $3.46 billion and immediately backed it up with raised fiscal 2026 guidance — the kind of one-two punch that moves a stock.
Management bumped sales growth guidance to a range of 4.5% to 5.5%, while non-GAAP diluted EPS guidance now sits at $5.29 to $5.39. Those aren't token upgrades — they signal that operating margins and cash flow are trending in the right direction, not just revenue at the top line.
Read more Trump Rules Out Iran Strike Before November Midterms →
Wall Street is on board, but cautiously. The analyst consensus lands at "Moderate Buy," with a price target that still sits above where the stock is trading today. That gap between current price and target is your tradeable angle. If Schein executes against this new outlook, the street has room to chase it higher.
The key word here is execution. Raised guidance is only as good as the follow-through. Watch for margin discipline and cash flow consistency in Q3 — those will be the tell. If the company can hold expanded margins while sustaining this revenue pace, analysts could get more aggressive with upgrades.
This is a name worth keeping on your watchlist, especially if you're looking for healthcare sector exposure with a near-term catalyst already baked in. Continue reading at AD HOC NEWS.
